Status:

COMPLETED

Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.

Lead Sponsor:

Tactile Medical

Conditions:

Breast Cancer Lymphedema

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

The objective of this study is to demonstrate the feasibility of using the Flexitouch Plus with Cellular Connectivity (FT-CC) to monitor device use data to determine if reminders to patients impact co...

Detailed Description

This is a multi-center, on label, prospective, randomized, two-arm feasibility study that plans to enroll 30 female subjects in the United States. In an effort to reduce potential exposure to COVID-19...

Eligibility Criteria

Inclusion

  • Female 18 years of age or older
  • Diagnosis of unilateral breast cancer-related lymphedema
  • Willing and able to give informed consent (remotely or in person)
  • Willing and able to comply with the study protocol requirements and all study-related visit requirements, including the ability to participate remotely
  • Willing and able to receive text messages from sponsor

Exclusion

  • In-home use of PCD within previous 3 months
  • Phase-one CDT within previous 1 month or planned phase-one CDT during study participation Phase-one CDT defined as professionally administered MLD and/or multi-layer short stretch compressive bandaging.
  • Inability to be fit for PCD garments
  • Heart failure (acute pulmonary edema, decompensated acute heart failure)
  • Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)
  • Active skin or limb infection/inflammatory disease (acute cellulitis, other uncontrolled skin or untreated inflammatory skin disease) on the arms or trunk
  • Currently receiving treatment for cancer with curative intent.
  • Any circumstance where increased lymphatic or venous return is undesirable
  • Currently pregnant or trying to become pregnant
  • Known inability to receive cell phone connection where FT-CC therapy will be administered

Key Trial Info

Start Date :

August 13 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 19 2021

Estimated Enrollment :

29 Patients enrolled

Trial Details

Trial ID

NCT04432727

Start Date

August 13 2020

End Date

November 19 2021

Last Update

May 24 2023

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University of Louisville

Louisville, Kentucky, United States, 40202

2

St. Peter's Hospital

Albany, New York, United States, 12208

3

Samaritan Hospital Hildegard Medicus Cancer Center

Troy, New York, United States, 12180